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Abstract
Breast cancer is the most common cancer and the leading cause of cancer death in women. Although tamoxifen therapy is
successful for some patients, it does not provide adequate benefit for those who have estrogen receptor (ER)-negative
cancers. Therefore, we approached novel treatment strategies by combining two potential bioactive dietary supplements
for the reactivation of ERa expression for effective treatment of ERa-negative breast cancer with tamoxifen. Bioactive dietary
supplements such as green tea polyphenols (GTPs) and sulforaphane (SFN) inhibit DNA methyltransferases (DNMTs) and
histone deacetylases (HDACs), respectively, which are of central importance to cancer prevention. In the present study, we
have observed that treatment of ERa-negative breast cancer cells with GTPs and SFN alone or in combination leads to the
reactivation of ERa expression. The combination of 20 mg/mL GTPs and 5 mM SFN was found to be the optimal dose of ERa-
reactivation at 3 days in MDA-MB-231 cells. The reactivation of ERa expression was consistently correlated with ERa
promoter hypomethylation and hyperacetylation. Chromatin immunoprecipitation (ChIP) analysis of the ERa promoter
revealed that GTPs and SFN altered the binding of ERa-transcriptional co-repressor complex thereby contributing to ERa-
reactivation. In addition, treatment with tamoxifen in combination with GTPs and SFN significantly increased both cell death
and inhibition of cellular proliferation in MDA-MB-231 cells in comparison to treatment with tamoxifen alone. Collectively,
our findings suggest that a novel combination of bioactive-HDAC inhibitors with bioactive-demethylating agents is
a promising strategy for the effective treatment of hormonal refractory breast cancer with available anti-estrogens.
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Introduction
Breast cancer is the most frequently diagnosed cancer and the
leading cause of cancer death among women, accounting for 23%
of the total cancer cases and 14% of the cancer deaths [1]. One of
the important classifications of breast tumors is based on the
presence or absence of the estrogen receptor (ER). While the
majority of breast cancers are ER-positive, approximately 25–30%
are ER-negative [2,3]. Patients with ER-positive breast cancer
receive hormonal therapy using either selective estrogen receptor
modulators (SERMs) such as tamoxifen, raloxifene and lasofox-
ifene, or with aromatase inhibitors (AIs) such as anastrozole,
letrozole, and exemestene, and have a better prognosis. However,
treatment of patients with ER-negative tumor is challenging due to
the poor response to hormonal therapies in the absence ER
expression. Therefore alternative targeted therapies are aimed to
prevent and treat hormonal refractory breast cancers.
Recently, many studies have addressed the possibilities of
reactivation of ER expression in ER-negative breast cancer cells
for the effective treatment with available SERMs. Further, the
absence of ERa gene expression in ER-negative breast cancer is
largely due to epigenetic silencing instead of DNA mutation or
deletion of the ERa gene [4,5]. Previous studies have shown that
epigenetic silencing of ER is associated with DNA hypermethyla-
tion at the ER-promoter in ER-negative breast cancer cells [6,7].
In addition, histone modifications, specifically histone acetylation/
deactylations have also been implicated as common mechanisms
underlying ER silencing in human malignant mammary cells
[7,8]. Hence, treatment of ER-negative breast cancer cells with
DNA methyltransferase (DNMT) inhibitors such as 5-aza-29-
deoxycytidine and/or histone deacetylase (HDAC) inhibitors such
as trichostatin A (TSA) leads to the reactivation of ER expression,
underscoring the importance of DNMTs and HDACs in
maintaining the repressive environment at the ERa gene
[2,9,10]. However, the use of synthetic small molecules as the
DNMT and HDAC inhibitors for the ER-reactivation in ER-
negative breast tumor would be expected to result in too many
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vention and therapy.
Many studies have demonstrated the chemopreventive proper-
ties of green tea polyphenols (GTPs) and sulforaphane (SFN)
against various types of carcinoma through multiple mechanisms
such as anti-oxidant, induction of apoptosis, cell cycle regulation,
inhibition of angiogenesis and metastasis [11,12]. Further, (-)-
epigallocatechin-3-gallate (EGCG), a major constituent of GTPs,
is known to complex with the DNA methyltransferases (DNMTs)
which reduces methylating activity of many genes in cancer cells as
well as in mouse models [13,14]. The hypomethylation induced by
EGCG has been shown to be associated with reactivation of
methylation-silenced tumor suppressor genes such as p16
INK4a,
p21
CIP/WAF and the DNA mismatch repair gene, human mutL
homologue 1 (hMLH1), which eventually leads to tumor suppression
[13,15]. Further, SFN is a bioactive dietary supplement found in
cruciferous vegetables, that has an established histone deactylation
(HDAC) inhibition activity [16,17]. The HDAC inhibition activity
of SFN has been shown to lead to an increase in the global and
local histone acetylation status of a number of genes including
tumor promoter genes such as human telomerase reverse
transcriptase (hTERT) in breast cancer [18]. Both DNA methyl-
ation and histone acetylations have been the focus of considerable
attention in cancer prevention and therapy.
In addition to histone acetylation and promoter methylation,
histone modifications-mediated transcriptional regulation of ERa
expression has emerged. The ERa promoter is mostly hyper-
methylated in ER-negative breast cancer cells [6,7]. Hypermethy-
lation of CpG-islands may inhibit transcription by recruiting the
methyl-CpG binding domain (MBD) proteins or by interfering
with the recruitment and function of basal transcription factors or
transcriptional coactivators [2,7]. Similarly, ER-negative breast
cancer cells also display a relative depletion of acetyl-H3 and
acetyl-H4 which provide transcriptional repressive environment at
the ERa gene [8] Therefore, in the present study, we tested our
hypothesis that a combination of dietary DNMT and HDAC
inhibitors may lead to transcriptional activation of ERa expression
in ER-negative breast cancer cells. Our study demonstrates that
treatment of ER-negative breast cancer cells with GTPs and SFN
synergistically reactivates ERa expression through epigenetic
alteration of CpG methylation and histone acetylation-mediated
release of transcriptional inhibitor complex at the ERa promoter.
Furthermore, our findings suggest a novel dietary combination of
DNA methyltransferase and histone deacetylase inhibitors con-
tribute to ER re-expression in ER-negative breast cancer for the
effective treatment of hormonal refractory breast cancers (HRBCs)
with available SERMs.
Materials and Methods
Materials
GTPs and R, S-sulforaphane were purchased from LKT
laboratories (Minneapolis, MN). GTPs was freshly prepared at
a stock concentration of 1 mg/mL in sterile PBS just before
cellular treatment. SFN was prepared in DMSO and stored at
a stock concentration of 10 mmol/L at 220uC.
Cell culture and cell proliferation assay
The human breast cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). Breast cancer
MCF-7 [ER (+)], MDA-MB-453 [ER (2)] and MDA-MB-231
[ER (2)] cells were cultured as a monolayer in phenol-red–free
Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech Inc,
Manassas, VA) supplemented with 10% dextran-charcoal–
stripped fetal bovine serum (Atlanta Biologicals, Lawrenceville,
GA) and 1% penicillin/streptomycin (Mediatech, Herndon, VA)
as described previously [4,18]. Control MCF10A cells were also
procured from ATCC and maintained as described previously
[18]. MCF10A is a non-tumorigenic human breast epithelial cell
line and frequently used as a human breast cell control [19,20,21].
Cells were treated with GTPs or SFN and a combination of both
at the indicated concentrations. The medium with GTPs and SFN
was replaced every 24 h for the duration of the experiments. The
maximum concentration of DMSO in the culture medium was
0.1% (v/v). MTT assay was performed for assessing cellular
proliferation. Briefly, cells were plated at a density of 1610
4 cells
per well in 200 mL of complete medium containing different
concentrations of GTPs or SFN and combination of both in a 96-
well microtiter plate. Each treatment was repeated in 8 wells. The
cells were incubated for 96 h at 37uC in a humidified chamber at
the end of which MTT solution (50 mL, 5 mg/mL in media) was
added to each well and incubated for 2 h. The microtiter plate
containing the cells was centrifuged at 600 g for 5 min at 4uC. The
MTT solution was removed from the wells by aspiration and the
MTT-formazan crystals were dissolved in DMSO (150 mL).
Absorbance was recorded at 540 nm wavelength. To observe
the effects of 17b-estradiol (E2) (Sigma) and tamoxifen (Sigma) on
cellular apoptosis, MDA-MB-231 cells were treated from the
second day after treatments with GTPs and SFN.
Quantification of ERa expression by real-time PCR
Total RNA isolation and real-time quantification of ERa
expression were followed as described previously [4]. Total RNA
was extracted using the RNeasy kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Total RNA (2 mg)
was reverse-transcribed into cDNA using the iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA). The primers specific for
ERa (Hs01046818_ml) and glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) (Hs99999905_ml) were obtained from Inventorial Gene
Assay Products (Applied Biosystems, Foster City, CA). The
reaction was performed in a Bio-Rad MyiQ thermocycler (Bio-
rad, Hercules, CA) using platinum SYBR Green detection system
(Invitrogen, Carlsbad, CA). Thermal cycling was initiated at 94uC
for 4 min followed by 35 cycles of PCR (94uC, 15 s; 60uC, 30 s).
The calculations for determining the relative level of gene
expression were made using the cycle threshold (Ct) method.
The mean Ct values from duplicate measurements were used to
calculate the expression of the target gene using the formula: fold
change in gene expression, 2
2DDCt=2
2{DCt (treated samples)2DCt
(untreated control)}, where DCt=C t (ERa)2Ct (GAPDH).
Western blot analysis
Protein was extracted from cultured cells using the RIPA-lysis
buffer (Upstate Biotechnology, Lake Placid, NY) following the
manufacturer’s protocol. For immunoblot analysis, 100 mgo f
protein was resolved on a 10% SDS-PAGE and transferred onto
nitrocellulose membrane. After incubation in blocking buffer for
1 h, the membranes were incubated with the primary antibodies
specific for ERa (NeoMarkers, Fremont, CA), DNMT1,
DNMT3a, DNMT3b, SUV39H1 (Santa Cruz Biotechnology,
Santa Cruz, CA), HDAC antibody sampler kit (cat# 9928; Cell
Signalling, Danvers, MA) and b-actin (Cell Signalling). The blot
was then washed with TBS and 0.05% (v/v) Tween-20 and
incubated with specific secondary antibody conjugated with
horseradish peroxidase. Protein bands were then visualized using
the ECL-detection system following the protocol of the manufac-
turer. The bands were analyzed by using Kodak 1D 3.6.1 image
software for the intensity and normalized with respective b-actin.
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Cells were grown on the sterile cover slips and treated with
GTPs and SFN for 3 days. After the treatment period, cells were
fixed with cold-ethanol, permeabilized with 0.1% Triton- X100 in
phosphate buffered saline (PBS), and washed with PBS for 10 min.
The cells were then blocked with 5% goat serum in PBS for
30 min, followed by incubation with 3% H2O2 for 20 min to
quench endogenous peroxidase. After washing the cells with PBS,
cells were incubated with 5- mC specific antibody (1:500, v/v,
Calbiochem, Gibbstown, NJ) for 1 h, followed by sequential
incubation of cells with biotinylated secondary antibody, and
HRP-conjugated streptavidin, and finally with diaminobenzidine
(DAB) substrate for 5-mC positive staining. Nuclei were counter-
stained with methyl green (Sigma).
South-western dot-blot analysis for 5-methyl cytosine (5-
mC)
Cells were treated with GTP and SFN for 3 days as described
above. Genomic DNA was isolated using the DNA Isolation Kit
(Qiagen, Maryland, MD) according to the manufacturer’s
instructions, and dot-blot analysis was performed as described
previously [22]. Briefly, 1 mg of genomic DNA was transferred
onto Hybond-ECL nitrocellulose membranes (Amersham Bios-
ciences, UK) using Bio-Dot Microfiltration Apparatus (Bio-Rad
Laboratories, Inc. Hercules, CA), and fixed by baking the
membrane for 30 min at 80uC. After blocking the non-specific-
binding sites, the membrane was incubated with the antibody
specific to 5-mC (1:500, v/v) followed by incubation with a HRP-
conjugated secondary antibody. The bands were then visualized
using the ECL-detection system following the protocol of the
manufacturer (Santa Cruz Biotechnology). The bands were
analyzed by using Kodak 1D 3.6.1 image software for the
intensity and equal DNA loading was verified by staining the
membranes with 0.2% methylene blue.
DNMTs activity assay
DNMTs activity was determined using a colorimetric DNMTs
activity assay kit (Epigentek, Brooklyn, NY) according to the
manufacturer’s instruction. The reaction was initiated by adding
20 mg of nuclear extracts, containing active DNMTs, to the
unique cytosine-rich DNA substrate-coated ELISA plate and
incubated for 60 min at 37uC. The methylated DNA can be
recognized with anti-5-methylcytosine antibody. The amount of
methylated DNA, which is proportional to enzyme activity, is
calorimetrically quantified at 450 nm.
HDACs and HATs activity assays
Cultured MDA-MB-231 cells were harvested at the indicated
time points and nuclear extracts were prepared using the nuclear
extraction reagent (Pierce, Rockford, IL). The activities of HDACs
(Active Motif, Carlsbad, CA) and HATs (Epigentek, Brooklyn,
NY) were performed using the colorimetric kit according to the
manufacturer’s instruction as described previously [18]. The
enzymatic activities of HDACs and HATs were detected by
a microplate reader at 450 nm.
Chromatin immunoprecipitation (ChIP) analysis
Chromatin immunoprecipitation was performed using the EZ-
ChIP kit according to the manufacturer’s instructions (Upstate
Biotechnology, Lake Placid, NY) as described previously [18].
MCF-7 cells were used as a positive control. Cells were cross-
linked with 1% formaldehyde at 37uC for 10 min, washed twice
with ice-cold PBS, re-suspended in SDS-lysis buffer (1% SDS,
50 mM Tris-HCL, pH 8.0, 10 mM EDTA and protease inhibitor
cocktail), and then sonicated to an average length of sheered
genomic DNA of approximately 400–1000 bp. The antibodies
used in the ChIP assays were ChIP-validated acetyl-histone H3,
acetyl-histone H3K9, acetyl-histone H4, trimethyl-histone H3K9
(Upstate Biotechnology), HDAC1, MeCP2, MBD1, SUV39H1
(Santa Cruz Biotechnology) and DNMT1 (Abcam, Cambridge,
MA). A ‘‘no antibody’’ control was also used to evaluate-ChIP
efficiency. ChIP-purified DNA was quantified by using quantita-
tive-PCR (qPCR) using the Platinum SYBR Green detection
system and q-PCR specific ERa primer (Invitrogen, Carlsbad, CA)
as described earlier [18,21]. The binding of various transcription
factors to the ERa promoter was analyzed by standard PCR
conditions as described previously [4]. Briefly, the ERa promoter
primers were forward-59-GAA CCG TCC GCA GCT CAA GAT
C-39, reverse-59-GTC TGA CCG TAG ACC TGC GCG TTG-
39, with a total of 30 cycles at 94uC for 30 s, 56uC for 30 s, 72uC
for 1 min and final extension was extended at 72uC for 5 min.
After amplification, PCR products were separated on 1.5%
agarose gels and visualized by ethidium bromide staining using
Kodak 1D 3.6.1 image software and quantified. Quantitative data
were analyzed by optical densitometry using ImageJ Software
version 1.36b (http://rsb.info.nih.gov/ij/).
Bisulfite sequencing analysis
The DNA methylation status of the ERa promoter was assayed
by sodium bisulfite methylation sequencing using the EpiTect-
Bisulfite modification kit following the manufacture’s protocol
(Qiagen, Valencia, CA). Approximately 2 mg of genomic DNA
was used for bisulfite modification and then amplified by PCR
using Go Taq mix (Promega, Madison, WI). Primers and PCR-
conditions were followed as described previously [4]. PCR
amplified DNA was purified using the QIAquick PCR purification
kit (Qiagen) and sequenced using the 3730 DNA Sequencer
(Applied Biosystems, Foster City, CA). Percent methylation was
calculated using the following formula: Number of methylated
CpG6100/total number of CpGs assessed.
Small interfering RNA (siRNA) knockdown of ERa
Approximately 2.2610
5 cells per well were placed in a 6-well
plate and allowed to incubate overnight. The ERa siRNA (Santa
Cruz Biotechnology) was made into 10 mM stock using nuclease
free water and 9 nM siRNA was delivered to the cells using the
Silencer siRNA Transfection kit (Ambion/Applied Biosystems,
TX, USA) according to the manufacturer’s instructions. siCON-
TROL Non-Targeting siRNA (Santa Cruz Biotechnology) was
used as a negative control. Treatments incorporating GTPs and
SFN with or without TAM were performed for an additional 72 h.
Cells were harvested and checked for ERa knockdown after 3 days
using western blot analysis.
Apoptosis assay
Breast cancer cells transfected with ERa and control siRNA
transfected cells were treated with the indicated concentrations of
GTPs and SFN with or without TAM for 72 h. The cells were
then lysed with nuclei lysis buffer provided for apoptosis assays
using the Cell Death Detection ELISA Kit (Roche, Palo Alto, CA)
as described previously [23]. Briefly, the cytoplasmic histone/
DNA fragments were extracted and incubated in microtiter plate
modules coated with anti-histone antibody. Subsequently, the
peroxidase-conjugated anti-DNA antibody was used for the
detection of immobilized histone/DNA fragments, followed by
color development with 2,29-azinobis(3-ethylbenzo-thiazoline-6-
sulfonic acid) substrate for peroxidase. The spectrophotometric
Epigenetics of Hormonal Refractory Breast Cancer
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(Bio-Rad Model 680, Hercules, CA) at 405 nm. Percent apoptosis
was calculated using the formula: (1006treatment cell absor-
bance/control cell absorbance)2100.
Statistical analysis
The statistical significance of differences between the values of
treated samples and controls were determined with Kruskal-Wallis
with Dunn’s post test using GraphPad Prism version 4.00 for
Windows, GraphPad Software, San Diego, California, USA
(www.graphpad.com). In each case, P,0.05 was considered
statistically significant.
Results
GTPs and SFN synergistically inhibits cellular proliferation
of ERa-negative breast cancer cells
First to examine whether GTPs and SFN have any synergistic
cellular proliferation inhibitory activity on human breast cancer
cells, we performed cell viability assay with GTP and SFN alone or
in combination treatments for 3 days. We intended to determine
the optimal dose that will induce ERa transcriptional activation
without causing cellular toxicity, thereby studying possible
mechanisms involved in the ERa-reactivation in ERa-negative
MDA-MB-231 cells. The MTT-cell viability assay was performed
with the MDA-MB-231 and MDA-MB-453 cells treated with
various concentrations of GTPs and SFN alone or in combinations
as shown in Fig. 1A. We observed a dose-dependent cell growth
inhibition with GTPs and SFN treatments in both ER-negative
MDA-MB-453 and MDA-MB-231 cells, which became significant
at 80 mg/ml and 40 mM, respectively. However, the combination
of GTPs and SFN synergistically induced cell growth inhibition at
20 mg/ml GTPs and 10 mM SFN in these ERa-negative cells. The
synergistic cell growth inhibitory effects were well pronounced at
higher doses of GTPs and SFN. Further, MDA-MB-231 showed
less cellular viability inhibitory effect than MDA-MB-453 at
indicated GTPs and SFN doses, which might be due to the triple-
negative in nature. Therefore, for further studies we chose MDA-
MB-231 cells with minimum effect and triple-negative in nature;
thereby we can study the mechanisms without toxicity. Control
MCF10A cells were slightly inhibited in cell growth with
combination of 40 mg/ml GTPs and 20 mM SFN after 3 days of
treatment, indicating that higher combination doses might be toxic
to the normal breast cells (Fig. 1B). These results indicate that
lower doses of combined GTPs and SFN selectively inhibit ERa-
negative breast cancer cells; however, the optimal doses required
for the transcriptional activation of ERa remained to be de-
termined in our subsequent studies.
GTPs and SFN activate ERa mRNA and protein expression
in ERa-negative MDA-MB-231 breast cancer cells
To determine the optimal dose of GTPs and SFN for the ERa
reactivation, MDA-MB-231 cells were treated with increasing
concentrations of GTPs and SFN for 3 days as shown in Fig. 2A.
GTPs induced ERa mRNA expression at a concentration as low as
10 mg/ml, but the maximum significant effect was observed at
20 mg/ml. Similarly, SFN induced significant ERa expression
starting from 5 mM and the maximum ERa reactivation was
observed at 10 mM doses. Furthermore, in combination treat-
ments, 20 mg/ml GTPs and 5 mM SFN were shown to induce
optimal significant synergistic reactivation of ERa mRNA in ERa-
negative MDA-MB-231 cells after 24 h of post-treatment com-
pared to non-treated control (Fig. 2B). However, although SFN at
10 mM alone achieved the maximum significant ERa reactivation
in MDA-MB-231 cells, in combination with GTPs the optimal
doses of SFN was found to be 5 mM (Fig. 2B). Further, the
combination of 20 mg/ml GTPs and 5 mM SFN at 72 h post-
treatment with MDA-MB-231 cells induced a significant
(P,0.001) ERa reactivation compared to the respective individual
doses of GTPs and SFN at 72 h (Fig. 2B). Western blot analysis
showed that the combination of GTPs and SFN significantly
reactivated ERa protein expression in ERa-negative MDA-MB-
231 cells after 24 h of post-treatment (Fig. 2C). The ERa
reactivation was considerably higher at 72 h of post-combinational
doses of 20 mg/ml GTPs and 5 mM SFN in MDA-MB-231 cells.
These results indicated that the low concentrations of GTPs and
SFN did not induce significant cellular toxicity, but induced
transcriptional and translational reactivation of ERa expression in
the ERa-negative human breast cancer cells. Based on these
results, we therefore chose to use the concentrations of GTPs and
SFN as optimized in Fig. 2 for subsequent experiments.
GTPs and SFN altered epigenetic enzymes expression
and their activity
Previous studies have shown that ERa activation is associated
with DNA methylation and histone modifications; we therefore
assessed epigenetic-modulating enzymatic activity of the DNMTs
(Fig. 3A), HDACs (Fig. 3B), HATs (Fig. 3B) and DNMTs as well as
HDACs expression (Fig. 3C)i nE R a-negative MDA-MB-231
breast cancer cells, using GTPs and SFN treatments. Interestingly,
GTPs and SFN significantly reduced HATs and HDACs activities,
respectively, at the optimal doses used as shown in Fig. 3B. This is
in accordance with previous studies that EGCG has a HAT
inhibitory activity, and SFN poses a HDACs inhibitory activity
[16,18,24]. However, the combination of GTPs with SFN
additively enhanced HDACs inhibitory activity of SFN in MDA-
MB-231 cells but not HATs inhibitory activity. Further, HDAC
expression analysis showed that the combination of GTPs with
SFN considerably inhibits HDAC1, HDAC4 and HDAC6
expression in MDA-MB-231 cells (Fig. 3C), in accordance with
HDAC inhibitory activity observed in Fig. 3B. It is known that
EGCG, an active compound present in GTPs, is a DNMTs
inhibitor; similarly we have also observed that GTPs treatment
considerably inhibited DNMTs activity and expression in MDA-
MB-231 cells (Fig. 3A and 3D). Interestingly, we found that SFN,
a HDACs inhibitor, also inhibits DNMTs activity significantly in
MDA-MB-231 cells (Fig. 3A). The combinations of GTPs and
SFN have more pronounced DNMTs inhibitory effects than when
administrated separately. The combination doses mediated in-
hibition of DNMTs expression could be an important contributing
factor in altering the binding of MBD-proteins at the ERa
promoter. To our surprise, not only DNMTs but also histone
methyltransferase, SUV39H1, is also inhibited by GTPs and SFN
(Fig. 3C). The GTPs- and SFN-mediated inhibition of DNMTs
and SUV39H1 expressions could be an important contributing
factor in facilitating demethylation of the ERa promoter, which
leads to transcriptional activation of ERa expression [8,25].
GTPs and SFN altered histone modifications and DNA
methylation of the ERa-promoter
It is well known that histone modifications and DNA
methylation play important roles in gene expression and
regulation, especially in ERa activation in breast cancer cells
[4,25]. Our studies have shown that treatment with the GTPs and
SFN significantly altered the activity as well as expression of
epigenetic modulating enzymes in ERa-negative MDA-MB-231
cells, suggesting a potential role of histone modifications and DNA
Epigenetics of Hormonal Refractory Breast Cancer
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termine changes in histone modifications of the ERa promoter by
GTPs and SFN treatment by different time intervals in MDA-MB-
231 cells. We found that GTPs and SFN treatment can increase
considerable enrichment of three histone acetylation chromatin
markers, acetyl H3 (ac-H3), acetyl-H3 at lysine 9 (ac-H3K9) and
ac-H4 in MDA-MB-231 cells after 48 h of post-treatment (Fig. 4A).
We also found a decrease in the methylation status of inactive
histone markers such as trimethyl-H3 lysine 9 (tri-me-H3K9) in
MDA-MB-231 cells with GTPs and SFN treatments (Fig. 4A).
Further, a significantly enriched level of histone acetylation and
decreased tri-me-H3K9 was more pronounced in the combination
treatments of GTPs and SFN at 48 h and 72 h, suggesting the
importance of dietary combination-induced ERa-reactivation in
ERa-negative breast cancer cells through histone modifications
(Fig. 4A). These changes of histone acetylation and deacetylation
allow transcriptional factors binding into the ER regulatory region
by maintaining a repressive environment [2,7].
Since the ERa promoter is mostly hypermethylated in ERa-
negative breast cancer cells, we assessed the methylation status of
the ERa promoter region from 266 to +356 covering 29 CpG
dinucleotides and various overlapping transcription factor binding
sites for 24 h, 48 h and 72 h (Fig. 4B). We used bisulfite-
sequencing to detect the ERa methylation patterns of GTPs and
SFN treated MDA-MB-231 human breast cancer cells. Untreated
MDA-MB-231 and MCF-7 cells served as controls. As shown in
Fig. 4B, control MDA-MB-231 breast cancer cells maintain a high
level of methylation at promoter sites at 54.0262.36%. Although
we found considerable inhibition in DNMTs expression levels with
GTPs and SFN treatments, we did not find any significant changes
in methylation status of the ERa promoter with GTPs and SFN
treated MDA-MB-231 compared with untreated MDA-MB-231
cells (Fig. 4B). This is in accordance with our previous study that
EGCG treatment does not induce significant methylation changes
in the CpG islands of the ERa promoter in MDA-MB-231 cells
[4]. In contrast, combination treatments of GTPs with SFN
significantly reduced ERa promoter methylation after 48 h post-
Figure 1. Combined GTPs and SFN synergistically inhibit cellular proliferation of ERa-negative breast cancer cells but has
negligible effect on control MCF10A cells. Human breast cancer MDA-MB-231 and MDA-MB-453 cells (panel A), and control MCF10A (panel B)
cells were treated with varying concentrations of GTPs (0–80 mg/mL) and SFN (0–40 mM) as well as a combination of both the compounds for 3 days.
Percent cell viability was obtained using MTT assay as described under Materials and Methods. Results were obtained from three independent
experiments, mean 6 SD. Statistical significance,
*P,0.05.
doi:10.1371/journal.pone.0037748.g001
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37748Figure 2. GTPs and SFN synergistically reactivated ERa expression in ERa-negative human breast cancer cells. A) GTPs and SFN at
indicated doses induced ERa re-expression in ERa-negative MDA-MB-231 human breast cancer cells after 72 h of post-treatments. B) Treatment with
GTPs or SFN and a combination of both of the compounds at indicated doses induced ERa re-expression in ERa-negative human breast cancer cells.
Relative mRNA levels of ERa in GTPs and SFN treated cells were quantified at 12, 24, 48 and 72 h using real-time PCR. Data are in triplicates from three
independent experiments and were normalized to GAPDH. The values were plotted against control as relative fold induction 6 SD. Significance
against nontreated control,
*P,0.05,
**P,0.001;
aP,0.05 against individual GTPs and SFN doses at the same time interval. C) ERa protein expression
with the treatment of GTPs or SFN alone or in combination at 12, 24, 48 and 72 h in MDA-MB-231 cells. ERa-positive MCF-7 cells served as a positive
control. Actin was used as an equal loading control.
doi:10.1371/journal.pone.0037748.g002
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with Trichostatin A (TSA), a histone deacetylase inhibitor, in
MDA-MB-231 cells [4]. Our results indicated that only combined
treatments of GTPs and SFN can induce significant DNA
hypomethylation at the ERa promoter. In summary, these results
suggest that histone modifications and DNA methylation contrib-
ute a major role in GTPs and SFN induced ERa reactivation in
ERa-negative human breast cancer cells.
GTPs and SFN altered the binding of transcription
complex to the ERa-promoter
Given the strong link between histone modification and DNA
methylation, we asked whether GTP- and SFN-induced ERa re-
expression is associated with reorganization of heterochromatin
structure at the epigenetically regulated ERa promoter in MDA-
MB-231 cells. Studies have shown that HDAC repressor complex,
HDAC1 and DNMT1 involves gene silencing by recruiting co-
repressor complexes to the methylated ERa promoter [26]. Studies
have also shown that disruption of transcriptional repressor multi-
molecular complex, HDAC1/DNMT1/SUV39H1, is associated
with ERa transcriptional activation in ERa-negative breast cancer
cells [8]. Therefore, ChIP-assays were performed to examine
GTPs- and SFN-mediated changes in these transcriptional re-
pressor complexes binding on the ERa promoter. As shown in
Fig. 5A–B, GTPs and SFN can considerably lower the binding of
these transcriptional repressor multi-molecular complexes to the
ERa promoter and this effect was significant when treated with
GTPs and SFN in combinations. Further, GTPs and SFN
combination treatment also significantly disrupted binding of
methyl-CpG binding domain (MBD) proteins, MeCP2 and
Figure 3. GTPs and SFN altered epigenetic enzymes expression and their activity in ERa-negative breast cancer cells. Breast cancer
MDA-MB-231 cells were treated with the indicated concentration of GTPs and SFN alone or in combinations of both for 3 days. Nuclear extracts were
prepared and 20 mg of protein was used to estimate DNMTs (panel A), HDAC and HATs (panel B) activities using the colorimetric assay kit as described
under Materials and Methods. Non-treated MCF-7 cells were used as a positive control. Values are representative of three independent experiments
and represented as percent control 6 SD; statistical significance against nontreated MDA-MB-231 control,
*P,0.05. C) Effect of GTPs and SFN alone or
in combinations of both on DNMTs, SUV39H1 and HDACs expression in ERa-negative human breast cancer MDA-MB-231 cells. Cell lysates were
prepared at 3 days of post-treatments at the indicated doses followed by western blotting to analyze DNMTs (DNMT1, DNMT3a and DNMT3b),
HDACs (HDAC1, HDAC4 and HDAC6) and SUV39H1 expression. Non-treated MCF-7 cells were used as a positive control. Actin was used as an equal
loading control. D) Graphical representations are indicative of relative band intensity of DNMTs expression in MDA-MB-231 cells, normalized with b-
actin. Values are mean band intensity of three independent blot 6 SD.
doi:10.1371/journal.pone.0037748.g003
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tion induced by GTPs and SFN at the ERa promoter (Fig. 5A–B).
Collectively, these data suggest that the binding alterations of
transcriptional repressor complex to the ERa promoter contrib-
uted to the reactivation of ERa by the combination of dietary
DNMT and HDAC inhibitors, GTPs and SFN, respectively.
GTPs and SFN altered global DNA methylation in MDA-
MB-231 cells
Studies have shown that EGCG can induce hypomethylation in
various cell lines either by direct or indirect inhibition of DNA
methyltransferases [13,14,27]. We previously discovered that SFN
can also induce hypomethylation at the regulatory region of
hTERT through inhibition of DNMTs expressions [18]. There-
fore, we sought to determine the cause of GTPs and SFN
Figure 4. GTPs and SFN altered ERa promoter methylation and histone acetylations in MDA-MB-231 cells. A) MDA-MB-231 cells were
treated with GTPs and SFN alone, and in combinations as indicated for 24, 48 and 72 h. Histone modifications were analyzed by ChIP-qPCR using
chromatin markers including acetyl-H3, trimethyl-H3K9, acetyl-H3K9 and acetyl-H4 in the promoter region of ERa. Mouse IgG antibody controls were
assessed to verify the ChIP efficiency. The x-axis represents the different treatment groups, and the y-axis represents the relative enrichment of
individual binding factors [the percentage of immunoprecipitates compared with the corresponding input samples (defined as 100)]. The experiment
was repeated 3 times with triplicates in real-time PCR, and each point indicates the mean 6 SD. Significance against nontreated MDA-MB-231 control,
*P,0.05. B) GTPs and SFN altered ERa promoter DNA methylation in MDA-MB-231 breast cancer cells as assayed by bisulfite sequencing. MDA-MB-
231 cells were treated with the indicated concentration of GTPs and SFN for 24 h, 48 h and 72 h. Percent methylation was obtained by dividing the
number of methylated CpGs by the total number of CpGs (29) in the indicated ERa promoter region assessed. Values are representative of three
independent experiments and are represented as percent control 6 SD; statistical significance,
*P,0.05. C) The ERa promoter region used for bisulfite
sequencing is shown with PCR primer sequences, number of CpGs and the total amplification lengths.
doi:10.1371/journal.pone.0037748.g004
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MB-231 cells. We performed 5-methyl-cytosine (5-mC) immunos-
taining and dot-blot analysis to examine GTPs and SFN altered
global methylation in MDA-MB-231 cells. As shown in Fig. 6A,
GTPs-treatment considerably reduced 5-mC positive staining
compared with control cells. The effect of demethylation was
predominant in combination treatment of GTPs with SFN in
MDA-MB-231 cells. The results were further semi-quantitatively
analyzed by dot-blot analysis (Fig. 6B). Treatment of GTPs
resulted in a significant reduction in 5-mC levels in MDA-MB-231
cells compared with untreated MDA-MB-231 cells (Fig. 6C).
However, combined treatment of GTPs with SFN significantly
reduced 5-mC expression in MDA-MB-231 cells, resulting in
a synergistic global hypomethylation in CpG dinuclotides. These
results suggest that GTPs may have a broad effect on DNA
demethylation and this might be further accelerated by combina-
tion with SFN as observed in this study.
GTPs and SFN sensitized ERa-negative breast cancer cell
to SERM through epigenetic reactivation of ERa
Collectively our aforementioned observations conclude that the
combination of dietary DNMT and HDAC inhibitors, GTPs and
SFN, respectively, epigenetically reactivates ERa expression in
ERa-negative MDA-MB-231 cells. Furthermore, we sought to
determine whether the ERa-reactivation could be used along with
available SERMs such as tamoxifen therapy in hormonal re-
fractory breast cancer. We therefore investigated the changes in
cellular viability and apoptosis in ERa-negative MDA-MB-231
cells treated with GTPs and SFN alone or in combinations along
with tamoxifen (TAM). As shown in Fig. 7A, untreated MDA-MB-
231 cells showed an increased cellular proliferation with 17b-
estradiol (E2), an ERa-ligand activator. Treatments with GTPs
and 5-aza-29-deoxycytidine (AZC), a DNMT inhibitor, alone or in
combinations with TAM did not inhibit significant cellular
proliferation in MDA-MB-231 cells, which is likely due to the
limited ERa reactivations. However, MDA-MB-231 cells treated
Figure 5. GTPs and SFN altered binding of transcriptional factors to the ERa promoter in ERa-negative breast cancer cells. A) MDA-
MB-231 cells were treated with GTPs or SFN and a combination of both of the compounds as indicated for 3 days. Samples were prepared for ChIP-
assay and analyzed for the binding of ERa transcription repressor proteins including HDAC1, DNMT1, MeCP2, MBD1 and SUV39H1 together with
mouse IgG control. MCF-7 served as a positive control. PCR primers and conditions were used as described in Materials and Methods. Photographs are
representative of an experiment that was repeated in triplicates. B) ChIP data were calculated from the corresponding DNA fragments amplified by
PCR using Kodak 1D 3.6.1 image software; columns, mean; bars, SD; statistical significance,
*P,0.05. The relative binding ratio was calculated as the
ratio between the net intensity of each bound sample divided by the input and the untreated control sample divided by the input (bound/input)/
(control/input).
doi:10.1371/journal.pone.0037748.g005
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reduced cellular proliferation, likely due to the pronounced effect
of histone modifications as well as DNA demethylation-mediated
ERa activation in MDA-MB-231 cells. Furthermore, combined
treatment of GTP and SFN with TAM showed a significantly
greater effect in reducing cellular proliferation in ERa-negative
MDA-MB-231 cells. GTPs and SFN combined with TAM had
pronounced cellular proliferation inhibitory effect than the
combination of synthetic DNMT inhibitor, AZC, and HDAC
inhibitor, TSA, along with TAM (Fig. 7A). It was found that
MDA-MB-231 cells treated with 20 mg/mL GTPs and 10 mM
SFN induced a considerable level of cellular apoptosis in both
control as well as ERa-knockdown cells. Furthermore, combined
treatment with GTP and SFN showed a significantly higher
apoptosis in both control siRNA as well as ERa-knockdown
siRNA cells (P,0.05) (Fig. 7B). MDA-MB-231 cells treated with
GTPs and SFN combined with TAM had significantly higher
cellular apoptosis (P,0.01). Conversely, ERa knockdown MDA-
MB-231 cells treated with GTPs and SFN combined with TAM
induced a significantly lesser apoptosis than control siRNA treated
MDA-MB-231 cells (P,0.05). This might be the fact that GTPs
and SFN induced cellular apoptosis in MDA-MB-231 cells in both
Figure 6. GTPs and SFN induced global hypomethylation in ERa-negative breast cancer cells. MDA-MB-231 cells were treated with GTPs
or SFN and combination of both the compounds as indicated for 3 days and analyzed for 5-methycytosine (5-mC). A) Immunocytochemical detection
of DNA methylation using a 5-mC-specific antibody and counterstained with methyl green. 5-mC-positive staining is shown as dark brown.
Magnification 6400. Photomicrographs are representative of three independent experiments. B) Cellular DNA was extracted and dot-blot analysis
was performed for the presence of 5-mC. MCF-7 cells were used as a positive control and a no-DNA sample was used as a negative control. C)
Graphical representations are indicative of relative band intensity of 5-mC expression in breast cancer cells as shown. Values are mean band intensity
of three independent blot 6 SD; statistical significance,
*P,0.05.
doi:10.1371/journal.pone.0037748.g006
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ever, TAM required ERa-reactivation to induce significant level of
apoptosis in ERa-negative MDA-MB-231 cells at the low dose
used. Collectively, these results indicated that the combination of
GTPs and SFN can induce functional ERa re-expression and re-
sensitize ERa-negative breast cancer cells to available SERM,
TAM, which could provide an extremely important clinical
implication in potential application of combination of bioactive
dietary supplements as a therapeutic strategy for hormonal
refractory breast cancer.
Discussion
Epigenetic regulation has attracted considerable interest as
a molecular target for cancer prevention and therapy as well as
a target of many bioactive dietary components. Growing evidence
suggests that bioactive dietary components impact epigenetic
processes often involved with silencing of tumor suppressor genes,
activation of cell survival proteins and induction of cellular
apoptosis in many types of cancer [4,15,28,29]. GTPs and SFN
have been found to have anti-cancer properties in various cancers
through genetic and epigenetic mechanisms [11,12,14,16]. The
most abundant bioactive compound present in GTPs is catechins,
which include (–)-epicatechin (EC), (–)-epicatechin-3-gallate
(ECG), (–)-epigallocatechin (EGC) and (–)-epigallocatechin-3-
gallate (EGCG) [12,30]. Of these, EGCG accounts for more than
50% of the total polyphenol and effective content in green tea
[31]. EGCG, a well studied green tea polyphenol, has DNMTs
inhibitory activity, however, other catechins in GTPs such as (–)-
epicatechin (EC), (–)-epicatechin-3-gallate (ECG) and (–)-epigallo-
catechin (EGC) have also been found to share similar properties
although they are less efficient than EGCG [13,32]. Therefore, the
use of GTPs as a whole not only mimics the natural environment
but also enhances its synergistic epigenetic activity against various
cancers including breast cancer. Another bioactive dietary
supplement used in this study is sulforaphane (SFN), an
isothiocyanate naturally abundant in widely consumed cruciferous
vegetables, found to have HDACs inhibitory activity [16,17].
Therefore the focus of the current study is the use of combined
dietary DNMT and HDAC inhibitors for the prevention and
therapeutics of hormonal refractory breast cancer.
The epigenetics of ERa re-expression in ERa-negative breast
cancer cells has been studied in many laboratories, including our
laboratory, and has been of intense interest as a novel strategy for
the treatment of hormonal refractory breast cancer [4,7,25]. Since
ERa-negative tumors are difficult to treat with available SERMs
due to the lack of hormonal receptor, it is very crucial to formulate
a new treatment strategy for this type of hormonal refractory
breast cancer. Many studies have advanced our knowledge that
treatment with AZC, a DNMT inhibitor, and TSA, a HDAC
inhibitor, can reactivate ER expression in ER-negative breast
cancer cells, suggesting that epigenetic mechanisms play an
important role in ERa transcriptional regulations [7,9,25].
However, the use of synthetic molecules might induce potential
adverse side effects and higher cost. Therefore, the use of bioactive
dietary supplements as DNMT and HDAC inhibitors for the
reactivation of ER-expression in ER-negative breast cancer could
greatly mimic more natural dietary milieu, reduced treatment cost
and most importantly minimum adverse effects.
In the present study, we provided evidences that the combina-
tion of GTPs and SFN can induce re-expression of endogenous
ERa in ERa-negative MDA-MB-231 human breast cancer cells.
For the first time, our results demonstrate that the reactivation of
ERa by GTPs and SFN is mediated, at least partly, through the
epigenetic alterations in DNA methylation and chromatin
remodeling in ERa gene promoter. Recent evidences suggest that
epigenetic regulation is one of the most important molecular
events associated with ERa silencing in ERa-negative breast
cancers [2,7,9]. Recently, extensive studies have focused on
EGCG, a major component in GTPs, mediated DNMTs and
HAT inhibitory activity in various cancer cells, including breast
cancer cells [13,21,24]. Besides direct inhibition of DNMT by
EGCG, it was also reported that consumption of GTPs could lead
to a decrease in available S-adenosyl-L-methionine (SAM) and an
increase in S-adenosyl-L-homocysteine (SAH) and homocysteine
levels, thereby providing evidence of an indirect inhibition of DNA
methylation by EGCG/GTPs [27]. This conjecture is supported
by animal studies demonstrating that GTPs consumption through
drinking water can moderately decrease the level of SAM in the
intestine [14]. Beside HDAC inhibitory activity of SFN, we also
observed DNMTs inhibitory activity in human breast cancer cells.
This is in accordance with earlier findings that SFN-treatment
significantly inhibited HDAC activity and DNMTs expression in
breast cancer cells; however, we did not find any significant
alteration in HAT activity [18].
Several studies have reported that DNA methylation and
histone acetylation play important roles in ER transcriptional
regulation [7–9,25]. Together, our results suggest that GTPs and
SFN-induced down-regulation of DNMTs expression and histone
modifications is not only causing a repressive environment at the
ERa promoter but also altered the binding of transcriptional
repressor complex at the ERa promoter. This is confirmed further
with our ChIP-analysis that GTPs- and SFN-induced enrichment
of transcriptional active chromatin markers such as acetylated
histone H3, H3K9 and acetyl-H4 in ER-negative MDA-MB-231
cells, whereas chromatin inactive markers such as trimethyl-H3K9
was decreased. Importantly, we found that the histone H3K9
methyltransferase, SUV39H1, was released from the ER-promoter
since presence of SUV39H1 has been shown to be crucial for
maintenance of the H3-methylation and epigenetic control of
heterochromatin assembly in cancer cells [33,34]. In accordance,
we found that GTPs- and SFN-mediated release of SUV39H1
protein from ER promoter leads to suppression of trimethyl-H3K9
methylation in ER-negative MDA-MB-231 cells.
Studies have shown that CpG methylation of the ERa promoter
results in transcriptional ER silencing [26]. We found that
bioactive dietary DNA demethylating and histone deacetylating
agents such as GTPs and SFN can alter the binding of methyl-
CpG binding proteins, DNMT and HDAC, which are actively
involved in ERa transcriptional regulations [2,7]. Further our
results demonstrate that combinations of GTPs and SFN induced
the release of co-repressor complexes to the demethylated ERa
promoter and the disruption of transcriptional repressor multi-
molecular complex, HDAC1/DNMT1/SUV39H1, is actively
associated with ERa transcriptional activation in ERa-negative
breast cancer cells [8]. Further, it is also reported that release of
co-repressor complex leads to concomitant enrichment of ac-H3,
ac-H3K9 and ac-H4 [7]. Besides gene specific DNA demethyla-
tions, we also observed a global DNA hypomethylation by GTPs
and SFN in MDA-MB-231 cells. This might be due to the GTPs-
and SFN-mediated DNMTs inhibition in these human breast
cancer cells [15,18,21]. Taken together, it is apparent that
DNMTs-induced promoter demethylation and HDAC-associated
chromatin remodelling altered binding of transcriptional repressor
multi-molecular complex, which is closely, linked to the ERa re-
activation by GTPs and SFN in ERa-negative human breast
cancer cells.
Epigenetics of Hormonal Refractory Breast Cancer
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37748Figure 7. Combined treatments of GTPs and SFN sensitize ERa-negative breast cancer cells for tamoxifen therapy. MDA-MB-231 cells
treated with GTPs and SFN together with tamoxifen induced cellular apoptosis and inhibited cellular proliferation. A) ERa-negative MDA-MB-231
cellular viability in response to estradiol (10 nM) or tamoxifen (1 mM) alone, or in combination with GTP and SFN for 3 days. For a comparison, DNMTs
inhibitor, AZC (2.5 mM), and HDAC inhibitor, TSA (100 ng), also administrated to MDA-MB-231 cells. Cell viability was determined and plotted against
percent control. Data were obtained from three independent experiments, mean 6 SD. Statistical significance,
*P,0.05; **P,0.01. B) Knockdown of
ERa decreases GTPs- and SFN-sensitized, TAM-induced apoptosis in ERa-negative MDA-MB-231 cells. MDA-MB-231 cells were subjected to treatment
with 9 nM ERa-siRNA or control-siRNA. Cells were further treated with GTPs and SFN in combinations with or without TAM as indicated for 72 h. The
cells were lysed with nuclear lysis buffer and analyzed for apoptosis as described in Materials and Methods. Values are representative of three
independent experiments. Significance,
*P,0.05; **P,0.01. C) Effect of siRNA interference with ERa gene expression was assayed after 72 h using
specific antibodies to ERa and b-actin by western blot analysis. For ERa reactivation, 20 mg/mL GTPs and 5 mM SFN were used for 72 hrs. Data shown
are representative of the three separate experiments.
doi:10.1371/journal.pone.0037748.g007
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PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e37748In our potential application study, we have clearly demonstrated
that GTPs and SFN-mediated ERa-reactivation can be utilized for
the treatment with available SERMs, tamoxifen in ERa-negative
breast cancer cells. For the first time we demonstrated that the
combination of bioactive dietary supplements, GTPs and SFN can
reactivate ERa-expression in ERa-negative breast cancer cells
through DNA demethylation and histone modifications associated
epigenetic alterations. These findings are of importance not only
for understanding epigenetic regulation of the ERa gene but also
to provide evidence for the combined anticancer mechanism of
bioactive dietary DNMT and HDAC inhibitors in cancer
prevention and therapy.
In conclusion, our results suggest that the combination of
dietary bioactive supplements GTPs and SFN could enhance the
possible novel treatment strategy for hormonal refractory breast
tumors. Further, epigenetic regulation of ERa re-activation by
combination of GTPs and SFN could help in designing novel
therapeutic strategies. However, further studies with in vivo
transgenic models such as C3(1)/SV40 and Her2/neu are
necessary to validate our observations during different stages of
breast cancer progression. These in vivo mouse models can produce
ER-negative breast tumors which closely resemble the develop-
ment, progression and morphology of human breast tumors
[35,36]. These in vivo models can be manipulated to use for ER-
reactivation studies by potential bioactive dietary supplements
with more close resemblance to humans for the treatment of
hormonal refractory breast cancer in combination with available
SERMs.
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